

BR Pharm Co., Ltd.

#13, Sinpyeong-ro, Jijeong-myeon
26348 Wonju-si, Gangwon-do
Republic of Korea

Attn. Kim Seok Soon / CEO

Our reference

MIT/2024/P111

Contact person

Michal Tomin / +421 915 366 774

BRATISLAVA

16.5.2024

Subject: Notified Body Confirmation Letter

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as amended as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **3EC International a.s.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 2265 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

BR Pharm Co., Ltd.

#13, Sinpyeong-ro, Jijeong-myeon
26348 Wonju-si, Gangwon-do
Republic of Korea

SRN Number (if available): KR-MF-000027339

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.



In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by EU 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)

- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body,


3EC International a.s. 
 Hraničná 18, 821 05 Bratislava
 Slovak Republic
 ID No.: 36 789 003
 VAT No.: SK2022390073

Katarína Tomin Srdošová, PhD.

Director of NB2265

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Cross-Linked Hyaluronic Acid Filler Brand name: Revitrane Models: Revitrane HA20 Skinbooster: Content-2ml, Syringe- 3ml x 3ea;	Class III	N/A	2021-MDD/QS-057 NB2265 2021-MDD/DE-058 NB2265
Revitrane HA10 Classic: Content -1ml, Syringe-1m x x1ea, Needle size-30G x 2ea; Revitrane HA10 Volume: Content-1ml, Syringe-1ml x 1ea, Needle size-27G x 2ea; Revitrane HA10 Premium: Content-1ml, Syringe1ml x 1ea, Needle size-27G x 2ea; Revitrane Premium Sub-Q 1ml: Syringe-1ml x 1ea			

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2024/5/16	MIT/2024/P111	Initial issue